The Top 5 Biosimilar Articles for the Week of May 24

Here are the top 5 biosimilar articles for the week of May 24, 2021.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of May 24, 2021.

Number 5: Biosimilar developer Prestige BioPharma said it will build a $152 million research and development facility measuring 45,000 square meters in the Republic of Korea.

Number 4: Zydus Cadila launched the world’s first biosimilar form of trastuzumab emtansine, an antibody drug conjugate that both counteracts cancer cell growth and delivers a cytotoxic agent to the cancer cells and helps to destroy them.

Number 3: Education can increase physician motivation to prescribe biosimilars instead of costly originator products, panelists said in a Sandoz/Reuters discussion.

Number 2: Quebec became the fourth Canadian province to implement a mandatory biosimilar switching program. With some exceptions, the province is switching to a policy of allowing only biosimilars, if available, on lists of approved biologics.

Number 1: A study funded by AbbVie finds support for maintaining patients on originator rheumatic agents, such as Humira (adalimumab), rather than switching to biosimilars.

To read all of these articles and more, visit centerforbiosimilars.com.